Please assess the completion status of the following clinical trial:

Trial Title: Paradigm Shift in the Treatment of Patients With ACS

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men or non-pregnant women \>18 years of age and \< 75 years of age~* Patients undergo cardiac catheterization for ACS. Patients with STEMI, NSTEMI, and UAP will be included. STEMI will be defined as continuous chest pain for \>30 minutes, arrival at the hospital within 12 hours from chest pain onset, ST-segment elevation \>0.1 mV in at least two contiguous leads, or new left bundle-branch block on the 12-lead electrocardiogram (ECG), and elevated cardiac markers (troponin T/I or creatine kinase-MB). NSTEMI will be defined as a progressive crescendo pattern of angina or angina at rest, in the absence of ST-segment elevation on the 12-lead ECG, with elevated cardiac markers. UAP will be defined as new onset angina, progressive crescendo pattern of angina, or angina at rest.~* Culprit lesion located in a native coronary artery~* TIMI flow grade 3 and diameter stenosis \< 70% on angiogram~* Definite erosion defined by OCT~* Patients able to provide written informed consent~Exclusion Criteria:~Left ventricular ejection fraction \< 30%.~* Life expectancy \< 1 year.~* Contraindication to the contrast media.~* Creatinine level \> 2.0 mg/dL or end-stage kidney disease.~* Serious liver dysfunction.~* Patients with hemodynamic or electrical instability (including shock).~* Any contraindication against the use of ticagrelor.~* Investigator considers the patient is not suitable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patients with ACS treated medically (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).